Design of ProCAs (Protein-Based Gd3+ MRI Contrast Agents) with High Dose Efficiency and Capability for Molecular Imaging of Cancer Biomarkers

Medicinal Research Reviews

Volumn 34, Issue 5, 2014, Pages 1070-1099

  Xue, Shenghui ^a   Qiao, Jingjuan ^a   Jiang, Jie ^a   Hubbard, Kendra ^a   White, Natalie ^a   Wei, Lixia ^a   Li, Shunyi ^a   Liu, Zhi Ren ^a   Yang, Jenny J ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Molecular imaging; MRI; Protein based contrast agent

Indexed keywords

CD2 ANTIGEN; GADOLINIUM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROTEIN BASED CONTRAST AGENT; TUMOR MARKER; UNCLASSIFIED DRUG; CONTRAST MEDIUM;

ACUTE TOXICITY; ARTICLE; CHRONIC TOXICITY; CIRCULATION TIME; DRUG DESIGN; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; HUMAN; IMAGE ENHANCEMENT; IN VITRO STUDY; IN VIVO STUDY; METAL BINDING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERMEABILITY; PROSTATE CANCER; CHEMISTRY; DOSE RESPONSE; PROCEDURES;

CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; GADOLINIUM; MAGNETIC RESONANCE IMAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 84905494725     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21313     Document Type: Article

References (190)

1. Cardenas-Rodriguez J, Howison CM, Matsunaga TO, Pagel MD. A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents. Magn Reson Imaging 2013;31(6):900-910.
2. Jones RA, Votaw JR, Salman K, Sharma P, Lurie C, Kalb B, Martin DR. Magnetic resonance imaging evaluation of renal structure and function related to disease: Technical review of image acquisition, postprocessing, and mathematical modeling steps. J Magn Reson Imaging 2011;33(6):1270-1283.
3. Gore JC, Manning HC, Quarles CC, Waddell KW, Yankeelov TE. Magnetic resonance in the era of molecular imaging of cancer. Magn Reson Imaging 2011;29(5):587-600.
4. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179(5):1193-1199.
5. Wang Z, Su MY, Nalcioglu O. Applications of dynamic contrast enhanced MRI in oncology: Measurement of tumor oxygen tension. Technol Cancer Res Treat 2002;1(1):29-38.
6. Mueller GC, Hussain HK, Carlos RC, Nghiem HV, Francis IR. Effectiveness of MR imaging in characterizing small hepatic lesions: Routine versus expert interpretation. AJR Am J Roentgenol 2003;180(3):673-680.
7. Xue S, Qiao J, Pu F, Cameron M, Yang JJ. Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5(2):163-179.
8. 1H MR spectroscopy. J Magn Reson Imaging 2013.
9. Zhao Q, Lee S, Kent M, Schatzberg S, Platt S. Dynamic contrast-enhanced magnetic resonance imaging of canine brain tumors. Vet Radiol Ultrasound 2010;51(2):122-129.
10. Major JL, Meade TJ. Bioresponsive, cell-penetrating, and multimeric MR contrast agents. Acc Chem Res 2009;42(7):893-903.
11. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006;35(6):512-523.
12. Nonat A, Giraud M, Gateau C, Fries PH, Helm L, Mazzanti M. Gadolinium(III) complexes of 1, 4, 7-triazacyclononane based picolinate ligands: Simultaneous optimization of water exchange kinetics and electronic relaxation. Dalton Trans 2009 38:8033-8046.
13. Weinmann H-J, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 2003;46(1):33-44.
14. Frydrychowicz A, Lubner MG, Brown JJ, Merkle EM, Nagle SK, Rofsky NM, Reeder SB. Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging 2012;35(3):492-511.
15. Robinson PJ. Imaging liver metastases: Current limitations and future prospects. Br J Radiol 2000;73(867):234-241.
16. Weiss CR, Nour SG, Lewin JS. MR-guided biopsy: A review of current techniques and applications. J Magn Reson Imaging 2008;27(2):311-325.
17. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 2007;243(1):148-157.
18. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007;18(10):2636-2643.
19. Gibby WA, Gibby KA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol 2004;39(3):138-142.
20. Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics 2009;29(6):1565-1574.
21. Grobner T. Gadolinium-A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
22. Thomsen HS, Morcos SK, Dawson P. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 2006;61(11):905-906.
23. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5(7):491-502.
24. Clarkson RB. Blood-pool MRI contrast agents: Properties and characterization. Top Curr Chem 2002;221:201-235.
25. Wedeking P, Sotak CH, Telser J, Kumar K, Chang CA, Tweedle MF. Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. Magn Reson Imaging 1992;10(1):97-108.
26. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. Eur Radiol 2007;17(12):3017-3024.
27. Caravan P, Comuzzi C, Crooks W, McMurry TJ, Choppin GR, Woulfe SR. Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 2001;40(9):2170-2176.
28. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol 2006;60(3):314-323.
29. Adzamli K, Periasamy MP, Spiller M, Koenig SH. NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent. Invest Radiol 1999;34(6):410-414.
30. Kirchin MA, Runge VM. Contrast agents for magnetic resonance imaging: Safety update. Top Magn Reson Imaging 2003;14(5):426-435.
31. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1(3):128-137.
32. Villaraza AJ, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: The interplay between size, function, and pharmacokinetics. Chem Rev 2010;110(5):2921-2959.
33. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8(4):467-481.
34. Kumar K, Tweedle MF, Malley MF, Gougoutas JZ. Synthesis, stability, and crystal-structure studies of some Ca2+, Cu2+ and Zn2+ complexes of macrocyclic polyamino carboxylates. Inorg Chem 1995;34(26):6472-6480.
35. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, Witte S, McMurry TJ, Walovitch RC. MS-325: Albumin-targeted contrast agent for MR angiography. Radiology 1998;207(2):529-538.
36. Caravan P. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: Design and mechanism of action. Acc Chem Res 2009;42(7):851-862.
37. Choi HS, Liu W, Misra P, Tanaka E, Zimmer JP, Itty Ipe B, Bawendi MG, Frangioni JV. Renal clearance of quantum dots. Nat Biotechnol 2007;25(10):1165-1170.
38. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res 2000;60(24):6964-6971.
39. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001;81(4):1930-1937.
40. Lund U, Rippe A, Venturoli D, Tenstad O, Grubb A, Rippe B. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. Am J Physiol Renal Physiol 2003;284(6):F1226-1234.
41. Tweedle MF. The ProHance story: The making of a novel MRI contrast agent. Eur Radiol 1997;7(Suppl 5):225-230.
42. Toth E, Helm L, Merbach AE. Relaxivity of MRI contrast agents. In: Krause W, Ed. Contrast Agents I: Magnetic Resonance Imaging. Volume 221, Topics in Current Chemistry. New York: Springer-Verlag; 2002. p 61-102.
43. Solomon I. Relaxation processes in a system of two spins. Phys Rev 1955;99:559-565.
44. Bloembergen N. Proton relaxation times in paramagnetic solutions. J Chem Phys 1957;27:572-573.
45. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imaging 2009;4(2):89-100.
46. Bloembergen N, Morgan R. Theory of proton relaxation by Mn2+ ions in solution. J Chem Phys 1961;34:842.
47. McLachlan AD. Line widths of electron resonance spectra in solution. Proc R Soc Lond A 1964;280:271-288.
48. White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41(3):272-278.
49. Aime S, Gianolio E, Terreno E, Giovenzana GB, Pagliarin R, Sisti M, Palmisano G, Botta M, Lowe MP, Parker D. Ternary Gd(III)L-HSA adducts: Evidence for the replacement of inner-sphere water molecules by coordinating groups of the protein. Implications for the design of contrast agents for MRI. J Biol Inorg Chem 2000;5(4):488-497.
50. Aime S, D'Amelio N, Fragai M, Lee YM, Luchinat C, Terreno E, Valensin G. A paramagnetic probe to localize residues next to carboxylates on protein surfaces. J Biol Inorg Chem 2002;7(6):617-622.
51. Doble DM, Botta M, Wang J, Aime S, Barge A, Raymond KN. Optimization of the relaxivity of MRI contrast agents: Effect of poly(ethylene glycol) chains on the water-exchange rates of Gd(III) complexes. J Am Chem Soc 2001;123(43):10758-10759.
52. Raymond KN, Pierre VC. Next generation, high relaxivity gadolinium MRI agents. Bioconjug Chem 2005;16(1):3-8.
53. Datta A, Raymond KN. Gd-hydroxypyridinone (HOPO)-based high-relaxivity magnetic resonance imaging (MRI) contrast agents. Acc Chem Res 2009;42(7):938-947.
54. Werner EJ, Datta A, Jocher CJ, Raymond KN. High-relaxivity MRI contrast agents: Where coordination chemistry meets medical imaging. Angew Chem Int Ed Engl 2008;47(45):8568-8580.
55. De Leon-Rodriguez LM, Lubag AJ, Malloy CR, Martinez GV, Gillies RJ, Sherry AD. Responsive MRI agents for sensing metabolism in vivo. Acc Chem Res 2009;42(7):948-957.
56. Thompson MK, Doble DM, Tso LS, Barra S, Botta M, Aime S, Raymond KN. Hetero-tripodal hydroxypyridonate gadolinium complexes: Syntheses, relaxometric properties, water exchange dynamics, and human serum albumin binding. Inorg Chem 2004;43(26):8577-8586.
57. Werner EJ, Avedano S, Botta M, Hay BP, Moore EG, Aime S, Raymond KN. Highly soluble tris-hydroxypyridonate Gd(III) complexes with increased hydration number, fast water exchange, slow electronic relaxation, and high relaxivity. J Am Chem Soc 2007;129(7):1870-1871.
58. Yang JJ, Yang J, Wei L, Zurkiya O, Yang W, Li S, Zou J, Zhou Y, Maniccia AL, Mao H, Zhao F, Malchow R, Zhao S, Johnson J, Hu X, Krogstad E, Liu ZR. Rational design of protein-based MRI contrast agents. J Am Chem Soc 2008;130(29):9260-9267.
59. Polasek M, Sedinova M, Kotek J, Vander Elst L, Muller RN, Hermann P, Lukes I. Pyridine-N-oxide analogues of DOTA and their gadolinium(III) complexes endowed with a fast water exchange on the square-antiprismatic isomer. Inorg Chem 2009;48(2):455-465.
60. Werner EJ, Kozhukh J, Botta M, Moore EG, Avedano S, Aime S, Raymond KN. 1, 2-Hydroxypyridonate/terephthalamide complexes of gadolinium(III): Synthesis, stability, relaxivity, and water exchange properties. Inorg Chem 2009;48(1):277-286.
61. Endres PJ, MacRenaris KW, Vogt S, Meade TJ. Cell-permeable MR contrast agents with increased intracellular retention. Bioconjug Chem 2008;19(10):2049-2059.
62. Lucas RL, Benjamin M, Reineke TM. Comparison of a tartaric acid derived polymeric MRI contrast agent to a small molecule model chelate. Bioconjug Chem 2008;19(1):24-27.
63. Karfeld-Sulzer LS, Waters EA, Davis NE, Meade TJ, Barron AE. Multivalent protein polymer MRI contrast agents: Controlling relaxivity via modulation of amino acid sequence. Biomacromolecules 2010;11(6):1429-1436.
64. Briley-Saebo KC, Geninatti-Crich S, Cormode DP, Barazza A, Mulder WJ, Chen W, Giovenzana GB, Fisher EA, Aime S, Fayad ZA. High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. J Phys Chem B 2009;113(18):6283-6289.
65. Song Y, Kohlmeir EK, Meade TJ. Synthesis of multimeric MR contrast agents for cellular imaging. J Am Chem Soc 2008;130(21):6662-6663.
66. Overoye-Chan K, Koerner S, Looby RJ, Kolodziej AF, Zech SG, Deng Q, Chasse JM, McMurry TJ, Caravan P. EP-2104R: A fibrin-specific gadolinium-based MRI contrast agent for detection of thrombus. J Am Chem Soc 2008;130(18):6025-6039.
67. Caravan P, Das B, Dumas S, Epstein FH, Helm PA, Jacques V, Koerner S, Kolodziej A, Shen L, Sun WC, Zhang Z. Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Angew Chem Int Ed Engl 2007;46(43):8171-8173.
68. Nair SA, Kolodziej AF, Bhole G, Greenfield MT, McMurry TJ, Caravan P. Monovalent and bivalent fibrin-specific MRI contrast agents for detection of thrombus. Angew Chem Int Ed Engl 2008;47(26):4918-4921.
69. Artemov D, Bhujwalla ZM, Bulte JW. Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol 2004;5(6):485-494.
70. Cheng Z, Tsourkas A. Paramagnetic porous polymersomes. Langmuir 2008;24(15):8169-8173.
71. Kaneshiro TL, Jeong EK, Morrell G, Parker DL, Lu ZR. Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiography. Biomacromolecules 2008;9(10):2742-2748.
72. Plush SE, Woods M, Zhou YF, Kadali SB, Wong MS, Sherry AD. Nanoassembled capsules as delivery vehicles for large payloads of high relaxivity Gd3 +agents. J Am Chem Soc 2009;131(43):15918-15923.
73. Moriggi L, Cannizzo C, Dumas E, Mayer CR, Ulianov A, Helm L. Gold nanoparticles functionalized with gadolinium chelates as high-relaxivity MRI contrast agents. J Am Chem Soc 2009;131(31):10828-10829.
74. Kielar F, Tei L, Terreno E, Botta M. Large relaxivity enhancement of paramagnetic lipid nanoparticles by restricting the local motions of the Gd(III) chelates. J Am Chem Soc 2010;132(23):7836-7837.
75. Cheng Z, Thorek DL, Tsourkas A. Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl 2010;49(2):346-350.
76. Zhang J, Fatouros PP, Shu C, Reid J, Owens LS, Cai T, Gibson HW, Long GL, Corwin FD, Chen ZJ, Dorn HC. High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality. Bioconjug Chem 2010;21(4):610-615.
77. Manus LM, Mastarone DJ, Waters EA, Zhang XQ, Schultz-Sikma EA, Macrenaris KW, Ho D, Meade TJ. Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett 2010;10(2):484-489.
78. Xing G, Yuan H, He R, Gao X, Jing L, Zhao F, Chai Z, Zhao Y. The strong MRI relaxivity of paramagnetic nanoparticles. J Phys Chem B 2008;112(20):6288-6291.
79. Misselwitz B, Schmitt-Willich H, Ebert W, Frenzel T, Weinmann HJ. Pharmacokinetics of Gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001;12(2-3):128-134.
80. Alric C, Taleb J, Le Duc G, Mandon C, Billotey C, Le Meur-Herland A, Brochard T, Vocanson F, Janier M, Perriat P, Roux S, Tillement O. Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J Am Chem Soc 2008;130(18):5908-5915.
81. Datta A, Hooker JM, Botta M, Francis MB, Aime S, Raymond KN. High relaxivity gadolinium hydroxypyridonate-viral capsid conjugates: Nanosized MRI contrast agents. J Am Chem Soc 2008;130(8):2546-2552.
82. Aime S, Castelli DD, Crich SG, Gianolio E, Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res 2009;42(7):822-831.
83. Helm L. Optimization of gadolinium-based MRI contrast agents for high magnetic-field applications. Future Med Chem 2010;2(3):385-396.
84. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn Reson Med 2006;55(2):309-315.
85. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: Theory and design. Chem Rev 1987;87(5):901-927.
86. Kowalewski J, Kruk D, Parigi G. NMR relaxation in solution of paramagnetic complexes: Recent theoretical progress for s >= 1. Adv Inorg Chem 2005;57:41-104.
87. Helm L. Relaxivity in paramagnetic systems: Theory and mechanisms. Prog Nucl Magn Reson Spectrosc 2006;49(1):45-64.
88. Bennett H, Brown R, Koenig S, Swartz H. Effects of nitroxides on the magnetic field and temperature dependence of 1/T1 of solvent water protons. Magn Reson Med 1987 4(2):93-111.
89. Hwang L, Freed JH. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. J Chem Phys 1975;63(9):4017-4025.
90. Freed JH. Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids II. Finite jumps and independent T1 processes. J Chem Phys 1978;68(9):4034-4037.
91. Bryant LH, Jr, Jordan EK, Bulte JW, Herynek V, Frank JA. Pharmacokinetics of a high-generation dendrimer-Gd-DOTA. Acad Radiol 2002;9(Suppl 1):S29-S33.
92. Bryant LH, Jr, Brechbiel MW, Wu C, Bulte JW, Herynek V, Frank JA. Synthesis and relaxometry of high-generation (G = 5, 7, 9, and 10) PAMAM dendrimer-DOTA-gadolinium chelates. J Magn Reson Imaging 1999;9(2):348-352.
93. Bryant LH, Jr, Hodges MW, Bryant RG. Test of electron delocalization effects on water-proton spin-lattice relaxation by bromination of [tetrakis(4-sulfonatopheny)porphine]manganese. Inorg Chem 1999;38(5):1002-1005.
94. Kobayashi H, Brechbiel MW. Dendrimer-based nanosized MRI contrast agents. Curr Pharm Biotechnol 2004;5(6):539-549.
95. Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, Brechbiel MW. Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation. Clin Cancer Res 2004;10(22):7712-7720.
96. Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Konishi J, Togashi K, Brechbiel MW. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn Reson Med 2001;46(4):781-788.
97. Kellar KE, Henrichs PM, Hollister R, Koenig SH, Eck J, Wei D. High relaxivity linear Gd(DTPA)-polymer conjugates: The role of hydrophobic interactions. Magn Reson Med 1997;38(5):712-716.
98. Vander Elst L, Chapelle F, Laurent S, Muller RN. Stereospecific binding of MRI contrast agents to human serum albumin: The case of Gd-(S)-EOB-DTPA (Eovist) and its (R) isomer. J Biol Inorg Chem 2001;6(2):196-200.
99. Behra-Miellet J, Briand G, Kouach M, Gressier B, Cazin M, Cazin JC. On-line HPLC-electrospray ionization mass spectrometry: A pharmacological tool for identifying and studying the stability of Gd3+ complexes used as magnetic resonance imaging contrast agents. Biomed Chromatogr 1998;12(1):21-26.
100. Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007;46(16):6632-6639.
101. Hanaoka K, Kikuchi K, Terai T, Komatsu T, Nagano T. A Gd3+-based magnetic resonance imaging contrast agent sensitive to beta-galactosidase activity utilizing a receptor-induced magnetization enhancement (RIME) phenomenon. Chemistry 2008;14(3):987-995.
102. Esqueda AC, Lopez JA, Andreu-de-Riquer G, Alvarado-Monzon JC, Ratnakar J, Lubag AJ, Sherry AD, De Leon-Rodriguez LM. A new gadolinium-based MRI zinc sensor. J Am Chem Soc 2009;131(32):11387-11391.
103. Zhang Z, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem Int Ed Engl 2005;44(41):6766-6769.
104. Lauffer RB, Brady TJ. Preparation and water relaxation properties of proteins labeled with paramagnetic metal chelates. Magn Reson Imaging 1985;3(1):11-16.
105. Wikstrom MG, Moseley ME, White DL, Dupon JW, Winkelhake JL, Kopplin J, Brasch RC. Contrast-enhanced MRI of tumors. Comparison of Gd-DTPA and a macromolecular agent. Invest Radiol 1989;24(8):609-615.
106. Brasch R, Pham C, Shames D, Roberts T, van Dijke K, van Bruggen N, Mann J, Ostrowitzki S, Melnyk O. Assessing tumor angiogenesis using macromolecular MR imaging contrast media. J Magn Reson Imaging 1997;7(1):68-74.
107. Matsumoto Y, Jasanoff A. Metalloprotein-based MRI probes. FEBS Lett 2013;587(8):1021-1029.
108. Chen Y, Naik SG, Krzystek J, Shin S, Nelson WH, Xue S, Yang JJ, Davidson VL, Liu A. Role of calcium in metalloenzymes: Effects of calcium removal on the axial ligation geometry and magnetic properties of the catalytic diheme center in MauG. Biochemistry 2012;51(8):1586-1597.
109. Shapiro MG, Westmeyer GG, Romero PA, Szablowski JO, Kuster B, Shah A, Otey CR, Langer R, Arnold FH, Jasanoff A. Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. Nat Biotechnol 2010;28(3):264-270.
110. Qiao J, Xue S, Pu F, White N, Jiang J, Liu ZR, Yang JJ. Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. J Biol Inorg Chem 2014; 19(2):259-270.
111. Sana B, Poh CL, Lim S. A manganese-ferritin nanocomposite as an ultrasensitive T2 contrast agent. Chem Commun 2012;48(6):862-864.
112. Sana B, Johnson E, Sheah K, Poh CL, Lim S. Iron-based ferritin nanocore as a contrast agent. Biointerphases 2010;5(3):FA48-52.
113. Bar-Shir A, Liu G, Chan KW, Oskolkov N, Song X, Yadav NN, Walczak P, McMahon MT, van Zijl PC, Bulte JW, Gilad AA. Human protamine-1 as an MRI reporter gene based on chemical exchange. ACS Chem Biol 2014;9(1):134-138.
114. Zhou G, Li Y, Liu Y, Ge C, Li W, Sun B, Li B, Gao Y, Chen C. Subcellular distribution of polyhydroxylated metallofullerene Gd C82(OH)22 in different tissues of tumor-bearing mice. J Nanosci Nanotechnol 2010;10(12):8597-8602.
115. Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wei L, Wang L, Yang H, Grossniklaus HE, Liu ZR, Yang JJ. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PloS One 2011;6(3):e18103.
116. Veronese FM, Mero A, Pasut G. Protein PEGylation, basic science and biological applications. In: Veronese FM, Ed. PEGylated Protein Drugs: Basic Science and Clinical Applications, Milestones in Drug Therapy. Birkhäuser Basel, Switzerland 2009. p 11-31.
117. Yang W, Wilkins AL, Li S, Ye Y, Yang JJ. The effects of Ca2+ binding on the dynamic properties of a designed Ca2+-binding protein. Biochemistry 2005;44(23):8267-8273.
118. de Lussanet QG, Langereis S, Beets-Tan RG, van Genderen MH, Griffioen AW, van Engelshoven JM, Backes WH. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology 2005;235(1):65-72.
119. Wilkins AL, Ye Y, Yang W, Lee HW, Liu ZR, Yang JJ. Metal-binding studies for a de novo designed calcium-binding protein. Protein Eng 2002;15(7):571-574.
120. Wang X, Zhao K, Kirberger M, Wong H, Chen G, Yang JJ. Analysis and prediction of calcium-binding pockets from apo-protein structures exhibiting calcium-induced localized conformational changes. Protein Sci 2010;19(6):1180-1190.
121. Wang X, Kirberger M, Qiu F, Chen G, Yang JJ. Towards predicting Ca2+-binding sites with different coordination numbers in proteins with atomic resolution. Proteins 2009;75(4):787-798.
122. Kirberger M, Yang JJ. Structural differences between Pb2+- and Ca2+-binding sites in proteins: Implications with respect to toxicity. J Inorg Biochem 2008;102(10):1901-1909.
123. Kirberger M, Wang X, Deng H, Yang W, Chen G, Yang JJ. Statistical analysis of structural characteristics of protein Ca2+-binding sites. J Biol Inorg Chem 2008;13(7):1169-1181.
124. Deng H, Chen G, Yang W, Yang JJ. Predicting calcium-binding sites in proteins - a graph theory and geometry approach. Proteins 2006;64(1):34-42.
125. Carroll A, Yang W, Ye Y, Simmons R, Yang JJ. Amyloid fibril formation by a domain of rat cell adhesion molecule. Cell Biochem Biophys 2006;44(2):241-249.
126. Zhou Y, Xue S, Chen Y, Yang JJ. Probing Ca2+-binding capability of viral proteins with the EF-hand motif by grafting approach. Methods Mol Biol 2013;963:37-53.
127. Zhou Y, Xue S, Yang JJ. Calciomics: Integrative studies of Ca2+-binding proteins and their interactomes in biological systems. Metallomics 2013;5(1):29-42.
128. Yanyi C, Shenghui X, Yubin Z, Jie YJ. Calciomics: Prediction and analysis of EF-hand calcium binding proteins by protein engineering. Sci China Chem 2010;53(1):52-60.
129. Zhou Y, Xue S, Yang JJ. Calcium and Viruses. In: Kretsinger R, Uversky V, Permyakov E, Eds. Encyclopedia of Metalloproteins. New York: Springer; 2013. p 415-424.
130. Yang JJ, Liu Z, Li S, Zhou Y, Jiang J, Xue S, Qiao J, Wei L. Contrast Agents, Methods for Preparing Contrast Agents, and Methods of Imaging. US Patent App. 12/935, 413; 2009.
131. Yang W, Wilkins AL, Ye Y, Liu ZR, Li SY, Urbauer JL, Hellinga HW, Kearney A, van der Merwe PA, Yang JJ. Design of a calcium-binding protein with desired structure in a cell adhesion molecule. J Am Chem Soc 2005;127(7):2085-2093.
132. Yang W, Jones LM, Isley L, Ye Y, Lee HW, Wilkins A, Liu ZR, Hellinga HW, Malchow R, Ghazi M, Yang JJ. Rational design of a calcium-binding protein. J Am Chem Soc 2003;125(20):6165-6171.
133. Pidcock E, Moore GR. Structural characteristics of protein binding sites for calcium and lanthanide ions. J Biol Inorg Chem 2001;6(5-6):479-489.
134. Moats RA, Fraser SE, Meade TJ. A "smart" magnetic resonance imaging agent that reports on specific enzymatic activity. Angew Chem Int Edit 1997;36(7):726-728.
135. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, Fraser SE, Meade TJ. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol 2000;18(3):321-325.
136. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent. AJR Am J Roentgenol 1984;142(3):619-624.
137. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366(6455):575-580.
138. Ogurusu T, Wakabayashi S, Shigekawa M. Functional characterization of lanthanide binding sites in the sarcoplasmic reticulum Ca(2+)-ATPase: Do lanthanide ions bind to the calcium transport site? Biochemistry 1991;30(41):9966-9973.
139. Biagi BA, Enyeart JJ. Gadolinium blocks low- and high-threshold calcium currents in pituitary cells. Am J Physiol 1990;259(3Pt 1):C515-520.
140. Artinian L, Zhong L, Yang H, Rehder V. Nitric oxide as intracellular modulator: Internal production of NO increases neuronal excitability via modulation of several ionic conductances. Eur J Neurosci 2012;36(10):3333-3343.
141. Caravan P, Greenwood JM, Welch JT, Franklin SJ. Gadolinium-binding helix-turn-helix peptides: DNA-dependent MRI contrast agents. Chem Commun 2003;20:2574-2575.
142. Liepold L, Anderson S, Willits D, Oltrogge L, Frank JA, Douglas T, Young M. Viral capsids as MRI contrast agents. Magn Reson Med 2007;58(5):871-879.
143. Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging 2009;30(6):1240-1248.
144. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: Relationship to chemical characteristics. Magn Reson Imaging 1992;10(4):641-648.
145. Laurent S, Elst LV, Copoix F, Muller RN. Stability of MRI paramagnetic contrast media: A proton relaxometric protocol for transmetallation assessment. Invest Radiol 2001;36(2):115-122.
146. Frenzel T, Lengsfeld P, Schirmer H, Hutter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43(12):817-828.
147. Seth R, Yang S, Choi S, Sabean M, Roberts EA. In vitro assessment of copper-induced toxicity in the human hepatoma line, Hep G2. Toxicol In Vitro 2004;18(4):501-509.
148. Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro 2004;18(5):703-710.
149. Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: In vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009;36(12):1244-1254.
150. Kok MB, Strijkers GJ, Nicolay K. Dynamic changes in 1H-MR relaxometric properties of cell-internalized paramagnetic liposomes, as studied over a five-day period. Contrast Media Mol Imaging 2011;6(2):69-76.
151. Li S, Jiang J, Zou J, Qiao J, Xue S, Wei L, Long R, Wang L, Castiblanco A, White N, Ngo J, Mao H, Liu ZR, Yang JJ. PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities. J Inorg Biochem 2012;107(1):111-118.
152. Barnhart JL, Kuhnert N, Bakan DA, Berk RN. Biodistribution of GdCl3 and Gd-DTPA and their influence on proton magnetic relaxation in rat tissues. Magn Reson Imaging 1987;5(3):221-231.
153. Morse DL, Gillies RJ. Molecular imaging and targeted therapies. Biochem Pharmacol 2010;80(5):731-738.
154. Allison M. The HER2 testing conundrum. Nat Biotechnol 2010;28(2):117-119.
155. Nunn AD, Linder KE, Tweedle MF. Can receptors be imaged with MRI agents? Q J Nucl Med 1997;41(2):155-162.
156. Delli Castelli D, Dastru W, Terreno E, Cittadino E, Mainini F, Torres E, Spadaro M, Aime S. In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. J Control Release 2010;144(3):271-279.
157. Kok MB, Hak S, Mulder WJ, van der Schaft DW, Strijkers GJ, Nicolay K. Cellular compartmentalization of internalized paramagnetic liposomes strongly influences both T1 and T2 relaxivity. Magn Reson Med 2009;61(5):1022-1032.
158. Kok MB, Strijkers GJ, Nicolay K. Dynamic changes in (1) H-MR relaxometric properties of cell-internalized paramagnetic liposomes, as studied over a five-day period. Contrast Media Mol Imaging 2011;6(2):69-76.
159. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003;49(3):403-408.
160. Geninatti Crich S, Barge A, Battistini E, Cabella C, Coluccia S, Longo D, Mainero V, Tarone G, Aime S. Magnetic resonance imaging visualization of targeted cells by the internalization of supramolecular adducts formed between avidin and biotinylated Gd3+ chelates. J Biol Inorg Chem 2005;10(1):78-86.
161. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4(5):623-626.
162. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004;64(21):7668-7672.
163. Frullano L, Rohovec J, Aime S, Maschmeyer T, Prata MI, de Lima JJ, Geraldes CF, Peters JA. Towards targeted MRI: New MRI contrast agents for sialic acid detection. Chemistry 2004;10(20):5205-5217.
164. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004;51(3):480-486.
165. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med 2005;53(3):621-627.
166. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM. Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001;104(11):1280-1285.
167. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003;63(11):2723-2727.
168. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM. Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007;25(4):667-680.
169. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res 2003;63(18):5838-5843.
170. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003;108(18):2270-2274.
171. Burtea C, Laurent S, Port M, Lancelot E, Ballet S, Rousseaux O, Toubeau G, Vander Elst L, Corot C, Muller RN. Magnetic resonance molecular imaging of vascular cell adhesion molecule-1 expression in inflammatory lesions using a peptide-vectorized paramagnetic imaging probe. J Med Chem 2009;52(15):4725-4742.
172. Akhtar AM, Schneider JE, Chapman SJ, Jefferson A, Digby JE, Mankia K, Chen Y, McAteer MA, Wood KJ, Choudhury RP. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One 2010;5(9):e12800.
173. Qiao J, Li S, Wei L, Jiang J, Long R, Mao H, Wang L, Yang H, Grossniklaus HE, Liu ZR, Yang JJ. HER2 targeted molecular MR imaging using a de novo designed protein contrast agent. PLoS One 2011;6(3):e18103.
174. Pathak AP, Artemov D, Bhujwalla ZM. Novel system for determining contrast agent concentration in mouse blood in vivo. Magn Reson Med 2004;51(3):612-615.
175. Glunde K, Artemov D, Penet MF, Jacobs MA, Bhujwalla ZM. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev 2010;110(5):3043-3059.
176. Yoo B, Pagel MD. An overview of responsive MRI contrast agents for molecular imaging. Front Biosci 2008;13:1733-1752.
177. Stephen RM, Gillies RJ. Promise and progress for functional and molecular imaging of response to targeted therapies. Pharm Res 2007;24(6):1172-1185.
178. Zhang X, Cai W, Cao F, Schreibmann E, Wu Y, Wu JC, Xing L, Chen X. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006;47(3):492-501.
179. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods 2009;48(2):193-199.
180. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008;49(11):1735-1738.
181. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008;60(1):1-42.
182. Wei L, Li S, Yang J, Ye Y, Zou J, Wang L, Long R, Zurkiya O, Zhao T, Johnson J, Qiao J, Zhou W, Castiblanco A, Maor N, Chen Y, Mao H, Hu X, Yang JJ, Liu ZR. Protein-based MRI contrast agents for molecular imaging of prostate cancer. Mol Imaging Biol 2011;13(3):416-423.
183. Jensen JA, Carroll RE, Benya RV. The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 2001;22(4):689-699.
184. Wei L, Li S, Yang J, Ye Y, Zou J, Wang L, Long R, Zurkiya O, Zhao T, Johnson J, Qiao J, Zhou W, Castiblanco A, Maor N, Chen Y, Mao H, Hu X, Yang JJ, Liu ZR. Protein-based MRI contrast agents for molecular imaging of prostate cancer. Mol Imaging Biol 2011;13(3):416-423.
185. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009;50(7):1168-1177.
186. Liu Z, Niu G, Wang F, Chen X. (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009;36(9):1483-1494.
187. Ho CL, Chen LC, Lee WC, Chiu SP, Hsu WC, Wu YH, Yeh CH, Stabin MG, Jan ML, Lin WJ, Lee TW, Chang CH. Receptor-binding, biodistribution, dosimetry, and micro-SPECT/CT imaging of 111In-[DTPA(1), Lys(3), Tyr(4)]-bombesin analog in human prostate tumor-bearing mice. Cancer Biother Radiopharm 2009;24(4):435-443.
188. Roy A, Kucukural A, Zhang Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nat Protoc 2010;5(4):725-738.
189. Zhang Y. I-TASSER: Fully automated protein structure prediction in CASP8. Proteins 2009;77(Suppl 9):100-113.
190. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform 2008;9:40.